Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Ruben A. Mesa, Catriona Jamieson, Ravi Bhatia, et al.
Journal of the National Comprehensive Cancer Network (2016) Vol. 14, Iss. 12, pp. 1572-1611
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Unravelling the biology of SCLC: implications for therapy
Joshua K. Sabari, Benjamin H. Lok, J. Laird, et al.
Nature Reviews Clinical Oncology (2017) Vol. 14, Iss. 9, pp. 549-561
Open Access | Times Cited: 405
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
Claire Harrison, Alessandro M. Vannucchi, Uwe Platzbecker, et al.
The Lancet Haematology (2017) Vol. 5, Iss. 2, pp. e73-e81
Closed Access | Times Cited: 264
Leukemia secondary to myeloproliferative neoplasms
Andrew Dunbar, Raajit K. Rampal, Ross L. Levine
Blood (2020) Vol. 136, Iss. 1, pp. 61-70
Open Access | Times Cited: 106
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Prithviraj Bose, Srđan Verstovšek
Blood (2017) Vol. 130, Iss. 2, pp. 115-125
Open Access | Times Cited: 99
JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
Prithviraj Bose, Srđan Verstovšek
HemaSphere (2020) Vol. 4, Iss. 4
Open Access | Times Cited: 60
Investigation and management of erythrocytosis
Siraj Mithoowani, Marissa Laureano, Mark Crowther, et al.
Canadian Medical Association Journal (2020) Vol. 192, Iss. 32, pp. E913-E918
Open Access | Times Cited: 58
Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy
Jay Y. Spiegel, Caroline McNamara, Theodore A. Kennedy, et al.
Blood Advances (2017) Vol. 1, Iss. 20, pp. 1729-1738
Open Access | Times Cited: 60
A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management
Benjamin Garmezy, Jordan K. Schaefer, Jessica Mercer, et al.
Blood Reviews (2020) Vol. 45, pp. 100691-100691
Closed Access | Times Cited: 41
Young Age Increases Risk of Lymph Node Positivity in Early-Stage Rectal Cancer
Joshua E. Meyer, Steven J. Cohen, Karen Ruth, et al.
JNCI Journal of the National Cancer Institute (2015) Vol. 108, Iss. 1, pp. djv284-djv284
Open Access | Times Cited: 44
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis
Tania Jain, Katie L. Kunze, M’hamed Temkit, et al.
Bone Marrow Transplantation (2018) Vol. 54, Iss. 2, pp. 204-211
Open Access | Times Cited: 44
The Role of New Technologies in Myeloproliferative Neoplasms
Giuseppe A. Palumbo, Stefania Stella, Maria Stella Pennisi, et al.
Frontiers in Oncology (2019) Vol. 9
Open Access | Times Cited: 41
Text-mining clinically relevant cancer biomarkers for curation into the CIViC database
Jake Lever, Martin Jones, Arpad Danos, et al.
Genome Medicine (2019) Vol. 11, Iss. 1
Open Access | Times Cited: 38
Allogeneic Stem Cell Transplantation in Myelofibrosis
Tania Jain, Ruben A. Mesa, Jeanne Palmer
Biology of Blood and Marrow Transplantation (2017) Vol. 23, Iss. 9, pp. 1429-1436
Open Access | Times Cited: 34
Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms
Rashmi Kanagal‐Shamanna, Jennelle C. Hodge, Tracy Tucker, et al.
Cancer Genetics (2018) Vol. 228-229, pp. 197-217
Open Access | Times Cited: 33
Hemorrhage in Essential Thrombocythemia or Polycythemia Vera: Epidemiology, Location, Risk Factors, and Lessons Learned from the Literature
Christophe Nicol, Karine Lacut, Brigitte Pan‐Petesch, et al.
Thrombosis and Haemostasis (2020) Vol. 121, Iss. 05, pp. 553-564
Open Access | Times Cited: 29
Disease Modification in Myelofibrosis: An Elusive Goal?
Pankit Vachhani, Srđan Verstovšek, Prithviraj Bose
Journal of Clinical Oncology (2022) Vol. 40, Iss. 11, pp. 1147-1154
Open Access | Times Cited: 18
Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms
Diego Carbonell, Julia Suárez‐González, María Chicano, et al.
Cancers (2019) Vol. 11, Iss. 9, pp. 1364-1364
Open Access | Times Cited: 29
Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group
Vikas Gupta, Sonia Cerquozzi, Lynda Foltz, et al.
JCO Oncology Practice (2020) Vol. 16, Iss. 7, pp. 351-359
Open Access | Times Cited: 27
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers
Jingrui Liu, Binhua Lv, Hewen Yin, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 24
Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States
Ruben A. Mesa, Ralph V. Boccia, Michael R. Grunwald, et al.
Clinical Lymphoma Myeloma & Leukemia (2018) Vol. 18, Iss. 9, pp. 590-596
Open Access | Times Cited: 27
The Rationale for Immunotherapy in Myeloproliferative Neoplasms
Lucia Masárová, Prithviraj Bose, Srđan Verstovšek
Current Hematologic Malignancy Reports (2019) Vol. 14, Iss. 4, pp. 310-327
Closed Access | Times Cited: 25
Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study
Michael R. Grunwald, David J. Kuter, Ivy Altomare, et al.
Clinical Lymphoma Myeloma & Leukemia (2019) Vol. 20, Iss. 4, pp. 219-225
Open Access | Times Cited: 23
Portal vein thrombosis patients harboring JAK2V617F have poor long-term outcomes despite anticoagulation
Leonard Naymagon, Douglas Tremblay, Nicole Zubizarreta, et al.
Journal of Thrombosis and Thrombolysis (2020) Vol. 50, Iss. 3, pp. 652-660
Closed Access | Times Cited: 23
Management of myelofibrosis after ruxolitinib failure
Prithviraj Bose, Srđan Verstovšek
Leukemia & lymphoma/Leukemia and lymphoma (2020) Vol. 61, Iss. 8, pp. 1797-1809
Open Access | Times Cited: 21
Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities
Giacomo Coltro, Giuseppe Gaetano Loscocco, Alessandro M. Vannucchi
International review of cell and molecular biology (2021), pp. 1-69
Closed Access | Times Cited: 20
Page 1 - Next Page

Scroll to top